Recent News

• 03.25.2026 - Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
• 02.24.2026 - Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
• 02.24.2026 - Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
• 02.23.2026 - Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

Recent Filings

• 03.05.2026 - 8-K Current report
• 02.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2026 - EX-99.1 EX-99.1
• 02.24.2026 - 144 Report of proposed sale of securities
• 02.24.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.24.2026 - 8-K Current report
• 02.24.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 02.12.2026 - 8-K Current report
• 02.09.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.05.2026 - 8-K Current report